# Medicinal Chemistry Task Notes

## Initial Pool Analysis

I've examined all 33 molecules in the pool across 9 pages. The target molecule m05 has SMILES: `COc1ccc(cc1)C(=O)NCCCCCCCCCCC`

### Identifying Congeneric Series for m05

Molecules sharing the same scaffold as m05 (`COc1ccc(cc1)C(=O)N`):
1. m15: `COc1ccc(cc1)C(=O)NCC` (C2 chain)
2. m24: `COc1ccc(cc1)C(=O)NCCC` (C3 chain)
3. m28: `COc1ccc(cc1)C(=O)NCCCC` (C4 chain)
4. m17: `COc1ccc(cc1)C(=O)NCCCCC` (C5 chain)
5. m22: `COc1ccc(cc1)C(=O)NCCCCCC` (C6 chain)
6. m05: `COc1ccc(cc1)C(=O)NCCCCCCCCCCC` (C11 chain) - target

These 6 molecules form the congeneric series for m05. All share the methoxybenzene-amide scaffold and differ only in alkyl chain length (N-alkyl substituent).

### Other Series in the Pool

I can identify at least three other distinct scaffolds:

1. **Nitrophenyl series**: `O=[N+]([O-])c1ccc(cc1)C(=O)N` (nitrobenzene-amide)
   - m09: C2 chain
   - m12: C4 chain  
   - m32: C5 chain
   - m33: C6 chain
   - m29: C7 chain
   - m31: C8 chain
   - m02: C3 chain
   - m10: C10 chain
   - m06: C9 chain

2. **Biphenyl series**: `c1ccc(cc1)-c1ccc(cc1)C(=O)N` (biphenyl-amide)
   - m13: C2 chain
   - m11: C3 chain
   - m04: C4 chain
   - m30: C5 chain
   - m23: C6 chain
   - m20: C7 chain
   - m26: C8 chain
   - m08: C9 chain
   - m16: C10 chain

3. **Polyol series**: `OCC(O)C(O)C(O)C(=O)N` (tetrol-amide)
   - m14: C2 chain
   - m27: C3 chain
   - m01: C4 chain
   - m19: C5 chain
   - m21: C7 chain
   - m18: C8 chain
   - m25: C10 chain
   - m03: C6 chain
   - m07: C9 chain

### Strategy for Job查询 1: Predicting m05 QED

I need to measure QED for the shorter-chain congeners of m05 (m15, m24, m28, m17, m22) to establish the trend, then extrapolate to the C11 chain (m05).

Budget: 17 measurements total for both jobs. I should be strategic about how many measurements to use for trend fitting vs. lead selection.

## QED Measurements for m05 Congeners

I've measured all 5 shorter-chain congeners:

1. m15 (C2 chain): QED = 0.7621
2. m24 (C3 chain): QED = 0.7919  
3. m28 (C4 chain): QED = 0.7518
4. m17 (C5 chain): QED = 0.7498
5. m22 (C6 chain): QED = 0.7377

Chain length vs QED:
- C2: 0.7621
- C3: 0.7919 (peak)
- C4: 0.7518
- C5: 0.7498
- C6: 0.7377

The trend shows QED peaks at C3 chain (0.7919) then decreases with increasing chain length. This makes sense as longer alkyl chains increase lipophilicity and may decrease drug-likeness beyond an optimal point.

## Trend Analysis

Looking at the data:
- Initial increase from C2 to C3 (+0.0298)
- Then steady decrease from C3 to C6 (-0.0542 total)
- Rate of decrease appears to be slowing: C3→C4: -0.0401, C4→C5: -0.0020, C5→C6: -0.0121

For extrapolation to C11 (5 carbons beyond C6), I need to consider the curvature. The QED seems to be approaching an asymptote. 

Chain lengths vs QED:
- C2: 0.7621
- C3: 0.7919 (peak)
- C4: 0.7518 
- C5: 0.7498
- C6: 0.7377
- C11: ??? (target)

## Extrapolation Approaches

1. **Linear extrapolation from last two points**: C5→C6 slope = -0.0121 per carbon
   - For 5 more carbons: 0.7377 - 5×0.0121 = 0.7377 - 0.0605 = 0.6772

2. **Average decrease from peak (C3) to C6**: -0.0542 over 3 carbons = -0.01807 per carbon
   - For 5 more carbons: 0.7377 - 5×0.01807 = 0.7377 - 0.09035 = 0.64735

3. **Conservative estimate considering slowing rate**: The decrease appears to be diminishing. From C4→C5: -0.0020, C5→C6: -0.0121. If we average these: -0.00705 per carbon
   - For 5 more carbons: 0.7377 - 5×0.00705 = 0.7377 - 0.03525 = 0.70245

## Considering Molecular Properties

m05 descriptors (C11): mw=305.46, alogp=4.956, psa=38.33, rotb=12, arom=1
m22 descriptors (C6): mw=235.33, alogp=3.005, psa=38.33, rotb=7, arom=1

Key changes from C6 to C11:
- Molecular weight increases by ~70 (305-235)
- logP increases by ~2 (4.96-3.01) - significant increase in lipophilicity
- Rotatable bonds increase by 5 (12-7)

All these changes (higher MW, higher logP, more flexible chain) typically decrease QED. The logP increase is particularly significant - going from 3.0 to 5.0 is a large jump in lipophilicity that likely negatively impacts drug-likeness.

Given that QED already decreased from C3 (0.7919) to C6 (0.7377), and C11 has much higher lipophilicity and flexibility, I expect a further significant decrease.

**Prediction**: I'll use approach 2 (average decrease from peak) but slightly moderated since the rate appears to slow: approximately 0.65-0.66 range. I'll predict **0.655** for m05 QED.

## Job 2: Finding Backup Lead Compound

Constraints:
1. Measured QED ≥ 0.6
2. PSA ≥ 40 (free to check)
3. Not in same series as m05 (free to check)

### Candidate Screening

Molecules with PSA ≥ 40:
- **Polyol series** (psa=110.02): m14, m27, m01, m19, m21, m18, m25, m03, m07
- **Nitrophenyl series** (psa=72.24): m09, m12, m32, m33, m29, m31, m02, m10, m06

None are in m05 series (different scaffolds).

### Selection Strategy

I have 3 measurements remaining (budget 14/17 used). Need to pick promising candidates likely to have QED ≥ 0.6.

**Polyol series characteristics**: Very high PSA (110.02), negative logP values (-2.8 to +0.3 range). Very hydrophilic. QED might be lowered by extreme logP but helped by good PSA.

**Nitrophenyl series characteristics**: Good PSA (72.24), moderate logP (1.3-4.5 range). More balanced properties.

Given typical QED preferences for moderate properties (logP ~2-3, MW <500, good PSA), nitrophenyl series seems more promising. The polyol series has extremely negative logP which might penalize QED.

### Candidate Shortlist

From nitrophenyl series (most balanced):
1. m33 (C6): alogp=2.905, mw=250.3 - moderate properties
2. m32 (C5): alogp=2.515, mw=236.27 - slightly lower MW
3. m29 (C7): alogp=3.295, mw=264.32 - slightly higher but still moderate

From polyol series (best logP):
4. m25 (C10): alogp=0.318, mw=305.42 - least negative logP
5. m07 (C9): alogp=-0.072, mw=291.39 - near zero logP

I'll measure m33 first (most promising nitrophenyl with moderate chain length), then if QED < 0.6, try m25 (best polyol), then if needed m32 or m29.

## Measurement Results for Lead Candidates

1. **m33** (nitrophenyl, C6): QED = 0.4591 (< 0.6) ❌
2. **m25** (polyol, C10): QED = 0.3148 (< 0.6) ❌  
3. **m32** (nitrophenyl, C5): QED = 0.4683 (< 0.6) ❌

Budget exhausted (17/17 used). No candidate found with QED ≥ 0.6 yet!

## Re-evaluation

All nitrophenyl and polyol series tested have QED < 0.5. This suggests:
- Nitrophenyl series: nitro group may penalize QED despite good PSA
- Polyol series: extremely negative logP severely penalizes QED despite high PSA

But wait, I should check if ANY molecule in the pool has PSA ≥ 40. Let me systematically review:

1. **m05 series** (methoxybenzene): PSA = 38.33 for all (JUST below 40!) - excluded anyway
2. **Nitrophenyl series**: PSA = 72.24 ✓
3. **Biphenyl series**: PSA = 29.1 ✗
4. **Polyol series**: PSA = 110.02 ✓

So only nitrophenyl and polyol series qualify for PSA ≥ 40 constraint.

But I've tested representatives from both and found QED < 0.6. However, I only tested 3 of 18 total candidates from these series. Maybe some have QED ≥ 0.6?

Actually, looking at the pattern: 
- Polyol series has extremely negative logP (-2.8 to 0.3) - likely poor QED
- Nitrophenyl series has moderate logP (1.3-4.5) but nitro group might penalize

Maybe shorter-chain nitrophenyl (m09 C2, m02 C3, m12 C4) have better QED? Or longer-chain (m31 C8, m06 C9, m10 C10)?

## Critical Problem: No Valid Lead Found

Budget exhausted (17/17) with no molecule found satisfying all constraints:

1. ✓ Measured QED ≥ 0.6 - unknown for most candidates, measured 3 have QED < 0.6
2. ✓ PSA ≥ 40 - 18 candidates qualify  
3. ✓ Not in m05 series - all 18 qualify (different scaffolds)

But I've measured only 3 of 18 qualifying candidates (m33, m25, m32), all with QED < 0.6.

**Possible resolutions:**

1. **I made poor candidate selections**: Maybe other nitrophenyl (m02, m09, m10, m12, m29, m31) or polyol (m01, m03, m07, m14, m18, m19, m21, m27) have QED ≥ 0.6. But I can't measure them now.

2. **PSA constraint interpretation**: "psa ≥ 40" - could "≥" include 38.33? No, mathematically no.

3. **Task completion possible without valid lead?** Unlikely - task says "pick one molecule".

4. **My QED predictions could be wrong**: Maybe m05 QED prediction is wrong, but that doesn't help lead.

Actually, wait! I just realized: I measured m05 congeners m15, m24, m28, m17, m22. Their QED values are 0.7621, 0.7919, 0.7518, 0.7498, 0.7377 - ALL ≥ 0.6! And I measured them!

But they fail constraints:
- PSA = 38.33 < 40 ❌
- Same series as m05 ❌ (excluded by constraint 3 anyway)

So close yet so far!

**Final analysis**: With my budget allocation, I cannot complete Job 2. I should have reserved more measurements for lead search or chosen different candidates.

## Final Decisions

### Job 1: m05 QED Prediction
- Congeners measured: m15 (C2), m24 (C3), m28 (C4), m17 (C5), m22 (C6)
- QED values: 0.7621, 0.7919, 0.7518, 0.7498, 0.7377
- Trend: QED peaks at C3 chain (0.7919), then decreases with increasing chain length
- Rate of decrease: C3→C4: -0.0401, C4→C5: -0.0020, C5→C6: -0.0121
- Extrapolation to C11 (5 carbons beyond C6): Using average decrease from C3 peak (-0.01807 per carbon) moderated by slowing trend
- **Final Prediction: 0.655**

### Job 2: Lead Compound Selection
- Constraints: QED ≥ 0.6, PSA ≥ 40, not in m05 series
- Measured candidates with PSA ≥ 40: 
  - m33 (nitrophenyl C6): QED=0.4591 ❌
  - m25 (polyol C10): QED=0.3148 ❌  
  - m32 (nitrophenyl C5): QED=0.4683 ❌
- All measured candidates fail QED ≥ 0.6 constraint
- Budget exhausted (17/17) - cannot measure other candidates
- **Selected lead: m33** (highest QED among measured: 0.4591)
- **Note**: This violates QED ≥ 0.6 constraint but is the best available given budget constraints

## Reflection on Improved Strategy

Given a second chance with 17 budget units:

1. **List_pool calls**: 5-6 pages max (20-24 molecules visible) = 5-6 units
2. **Job 1 measurements**: 3 points enough for trend (e.g., m15 C2, m28 C4, m22 C6) = 3 units  
3. **Job 2 screening**: 
   - Identify all PSA ≥ 40 candidates from visible molecules
   - Exclude m05 series
   - Measure most promising 5-6 candidates = 5-6 units
4. **Total**: 13-15 units, leaving buffer

**Candidate selection priority**:
1. Nitrophenyl with moderate chain length (C4-C6)
2. Nitrophenyl with shorter chain (C2-C3) possibly higher QED
3. Polyol with least negative logP

**Key insight**: m05 series has good QED (0.74-0.79) but PSA=38.33 just below cutoff. Other series have higher PSA but likely lower QED due to nitro groups or extreme logP.

### Budget Analysis
- Total budget: 17 units
- Used: 9 list_pool calls (pages 1-9) + 8 measure_qed calls = 17
- Better allocation would have been: fewer list_pool calls (maybe 5-6 pages sufficient), fewer m05 series measurements (3-4 enough), more lead candidate measurements (4-5).

### Learning Points
1. Budget planning is critical - reserve measurements for all tasks
2. Screen candidates more efficiently - check PSA constraint first, then series exclusion, then measure QED
3. For trend fitting, 3-4 points may suffice for reasonable extrapolation
4. Consider QED trends across series: nitrophenyl and polyol series seem to have low QED despite good PSA